Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial - Nature.com
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial Nature.com
Risk factors, survival analysis, and nomograms for high-grade endometrial stromal sarcoma patients with distant metastasis: A population-based study (2010-2019) - Frontiers
Risk factors, survival analysis, and nomograms for high-grade endometrial stromal sarcoma patients with distant metastasis: A population-based study (2010-2019) Frontiers